Literature DB >> 26014596

Gene-panel sequencing and the prediction of breast-cancer risk.

Douglas F Easton1, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey, David E Goldgar, D Gareth R Evans, Georgia Chenevix-Trench, Nazneen Rahman, Mark Robson, Susan M Domchek, William D Foulkes.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26014596      PMCID: PMC4610139          DOI: 10.1056/NEJMsr1501341

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  70 in total

Review 1.  Discovering moderate-risk breast cancer susceptibility genes.

Authors:  Antoinette Hollestelle; Marijke Wasielewski; John W M Martens; Mieke Schutte
Journal:  Curr Opin Genet Dev       Date:  2010-03-24       Impact factor: 5.578

2.  RAD50 gene mutations are not likely a risk factor for breast cancer in Poland.

Authors:  Maria Mosor; Iwona Ziółkowska-Suchanek; Krzysztof Roznowski; Marta Baranowska; Danuta Januszkiewicz-Lewandowska; Jerzy Nowak
Journal:  Breast Cancer Res Treat       Date:  2010-06-23       Impact factor: 4.872

Review 3.  Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.

Authors:  Tara M Friebel; Susan M Domchek; Timothy R Rebbeck
Journal:  J Natl Cancer Inst       Date:  2014-06       Impact factor: 13.506

4.  RAD51C is a susceptibility gene for ovarian cancer.

Authors:  Liisa M Pelttari; Tuomas Heikkinen; Deborah Thompson; Anne Kallioniemi; Johanna Schleutker; Kaija Holli; Carl Blomqvist; Kristiina Aittomäki; Ralf Bützow; Heli Nevanlinna
Journal:  Hum Mol Genet       Date:  2011-05-25       Impact factor: 6.150

Review 5.  Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.

Authors:  Sean V Tavtigian; Georgia Chenevix-Trench
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

6.  Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Authors:  Jirina Bartkova; Johanna Tommiska; Lenka Oplustilova; Kirsimari Aaltonen; Anitta Tamminen; Tuomas Heikkinen; Martin Mistrik; Kristiina Aittomäki; Carl Blomqvist; Päivi Heikkilä; Jiri Lukas; Heli Nevanlinna; Jiri Bartek
Journal:  Mol Oncol       Date:  2008-10-07       Impact factor: 6.603

7.  The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.

Authors:  Tuomas Heikkinen; Hanni Kärkkäinen; Kirsimari Aaltonen; Roger L Milne; Päivi Heikkilä; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

8.  Breast-cancer risk in families with mutations in PALB2.

Authors:  Antonis C Antoniou; Silvia Casadei; Tuomas Heikkinen; Daniel Barrowdale; Katri Pylkäs; Jonathan Roberts; Andrew Lee; Deepak Subramanian; Kim De Leeneer; Florentia Fostira; Eva Tomiak; Susan L Neuhausen; Zhi L Teo; Sofia Khan; Kristiina Aittomäki; Jukka S Moilanen; Clare Turnbull; Sheila Seal; Arto Mannermaa; Anne Kallioniemi; Geoffrey J Lindeman; Saundra S Buys; Irene L Andrulis; Paolo Radice; Carlo Tondini; Siranoush Manoukian; Amanda E Toland; Penelope Miron; Jeffrey N Weitzel; Susan M Domchek; Bruce Poppe; Kathleen B M Claes; Drakoulis Yannoukakos; Patrick Concannon; Jonine L Bernstein; Paul A James; Douglas F Easton; David E Goldgar; John L Hopper; Nazneen Rahman; Paolo Peterlongo; Heli Nevanlinna; Mary-Claire King; Fergus J Couch; Melissa C Southey; Robert Winqvist; William D Foulkes; Marc Tischkowitz
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

Review 9.  Risk of breast cancer in Lynch syndrome: a systematic review.

Authors:  Aung Ko Win; Noralane M Lindor; Mark A Jenkins
Journal:  Breast Cancer Res       Date:  2013-03-19       Impact factor: 6.466

10.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

Authors:  A J Lee; A P Cunningham; K B Kuchenbaecker; N Mavaddat; D F Easton; A C Antoniou
Journal:  Br J Cancer       Date:  2013-12-17       Impact factor: 7.640

View more
  314 in total

Review 1.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 2.  Reliable Biomarkers to Identify New and Recurrent Cancer.

Authors:  Edward R Sauter
Journal:  Eur J Breast Health       Date:  2017-10-01

Review 3.  Germline Mutations in Triple-Negative Breast Cancer.

Authors:  Eric Hahnen; Jan Hauke; Christoph Engel; Guido Neidhardt; Kerstin Rhiem; Rita K Schmutzler
Journal:  Breast Care (Basel)       Date:  2017-02-24       Impact factor: 2.860

4.  Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort.

Authors:  Charité Ricker; Julie O Culver; Katrina Lowstuter; Duveen Sturgeon; Julia D Sturgeon; Christopher R Chanock; William J Gauderman; Kevin J McDonnell; Gregory E Idos; Stephen B Gruber
Journal:  Cancer Genet       Date:  2016-01-12

5.  The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.

Authors:  A E Bunnell; C A Garby; E J Pearson; S A Walker; L E Panos; Joanne L Blum
Journal:  J Genet Couns       Date:  2016-06-09       Impact factor: 2.537

6.  Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.

Authors:  Helen Byers; Yvonne Wallis; Elke M van Veen; Fiona Lalloo; Kim Reay; Philip Smith; Andrew J Wallace; Naomi Bowers; William G Newman; D Gareth Evans
Journal:  Eur J Hum Genet       Date:  2016-06-08       Impact factor: 4.246

Review 7.  Update on Genetic Testing in Gynecologic Cancer.

Authors:  Susan M Domchek; Mark E Robson
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

8.  Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.

Authors:  Vanessa C Fernandes; Volha A Golubeva; Giuliano Di Pietro; Cara Shields; Kwabena Amankwah; Thales C Nepomuceno; Giuliana de Gregoriis; Renata B V Abreu; Carly Harro; Thiago T Gomes; Ricceli F Silva; Guilherme Suarez-Kurtz; Fergus J Couch; Edwin S Iversen; Alvaro N A Monteiro; Marcelo A Carvalho
Journal:  J Biol Chem       Date:  2019-02-14       Impact factor: 5.157

9.  Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

Authors:  Renan Gomes; Pricila da Silva Spinola; Ayslan Castro Brant; Bruna Palma Matta; Caroline Macedo Nascimento; Silvia Maria de Aquino Paes; Cibele Rodrigues Bonvicino; Anna Claudia Evangelista Dos Santos; Miguel Angelo Martins Moreira
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

10.  Prevalence of mutations in a diverse cohort of 3162 women tested via the same multigene cancer panel in a managed care health plan.

Authors:  Mónica Alvarado; George E Tiller; Joanie Chung; Reina Haque
Journal:  J Community Genet       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.